Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

fyi, the FDA granted Gleevec a priority review and approved the drug after only a 2 ½-month review time which, I believe, set a record for the fastest approval to market of any cancer treatment.

fwiw, I also agree with rkrw. if the trial was targeting just pts with the T315I mutation then I think approval could come very quickly; however, the trial will likely enroll pts who have failed two prior tki's and as such will likely need to demonstrate that the response is durable.